Condition: Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) · Sponsor: All India Institute of Medical Sciences
Hypo-fractionated radiotherapy reduces the OTT (overall treatment time) which may in turn reduce rapid accelerated repopulation of clonogenic cells during waiting period after surgery. If this holds true, there is a potential to achieve better loco-regional control in with PORT for HNSCC. There is a strong radiobiological and economic rationale for delivery hypo-fractionated radiotherapy in HNSCC. The HYPCON III trial will be aimed to reduce the number of fractions by 50% (30 fr to 15 fr)
This description comes directly from the study's public registry record.
Dr. Aman Sharma · +917018529339 · amans757@gmail.com
Always discuss trial participation with your own doctor first.
| Dr. Aman Sharma, Associate Professor, Radiation Oncology, NCI, AIIMS | Jhajjar, Haryana, India | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07573956